Full text is available at the source.
Abstract
A case of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurred in a diabetic patient taking Semaglutide.
- Clinical trials of Semaglutide did not report a significant increase in the risk of NAION.
- A recent retrospective cohort study suggested a possible association between NAION and GLP-1 receptor agonists.
- The association between NAION and Semaglutide is a subject of ongoing debate with conflicting study results.
- Clinicians and ophthalmologists should consider the potential association when evaluating the risk-benefit ratio for patients.
Simplified